FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer
View the full release here: https://www.businesswire.com/news/home/20240514522695/en/
- View the full release here: https://www.businesswire.com/news/home/20240514522695/en/
ARTBIO and FogPharma will co-develop novel HEARTs against multiple targets, leveraging FogPharma’s field-leading Helicon platform of tunable stabilized α-helical peptides and ARTBIO’s AlphaDirect™ platform for the development of ARTs using the best-in-class isotope, 212Pb. - The synergy of these two powerful platforms offers promising potential to create next-generation ARTs with properties ideal for precise delivery to tumors.
- “Our aim is to revolutionize outcomes for cancer patients in critical need.”
“Alpha radioligand therapy, and 212Pb in particular, has shown tremendous promise as a new class of radiopharmaceuticals. - This collaboration with FogPharma enables ARTBIO to advance next-generation therapeutics specifically designed to treat solid tumors,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO.